[go: up one dir, main page]

MX2015006758A - Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos. - Google Patents

Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.

Info

Publication number
MX2015006758A
MX2015006758A MX2015006758A MX2015006758A MX2015006758A MX 2015006758 A MX2015006758 A MX 2015006758A MX 2015006758 A MX2015006758 A MX 2015006758A MX 2015006758 A MX2015006758 A MX 2015006758A MX 2015006758 A MX2015006758 A MX 2015006758A
Authority
MX
Mexico
Prior art keywords
heavy chain
heterodimer
light chain
chain
pairs
Prior art date
Application number
MX2015006758A
Other languages
English (en)
Other versions
MX385344B (es
Inventor
Paula Irene Lario
Adam Louis Corper
Dunja Urosev
Stacey A L Tom-Yew
Dustin Weyland Blue Bleile
Thomas Spreter Von Kreudenstein
Surjit Dixit
Original Assignee
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50826996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015006758(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zymeworks Inc filed Critical Zymeworks Inc
Publication of MX2015006758A publication Critical patent/MX2015006758A/es
Publication of MX385344B publication Critical patent/MX385344B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medical Informatics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Evolutionary Biology (AREA)
  • Software Systems (AREA)
  • Biotechnology (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Databases & Information Systems (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Signal Processing (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente invención proporciona pares de heterodímeros que pueden comprender un primer heterodímero y un segundo heterodímero donde cada heterodímero comprende una cadena pesada de inmunoglobulina o fragmento de esta y una cadena ligera de inmunoglobulina o fragmento de esta. Al menos unos de los heterodímeros puede comprender una o más modificaciones de aminoácidos en los dominios VH y/o CL, una o más modificaciones de aminoácidos en los dominios VH y/o VL o una combinación de estas. El o los aminoácidos pueden ser parte de la interfaz entre la cadena ligera y la cadena pesada y se modifican típicamente para crear emparejamiento preferencial entre cada cadena pesada y una cadena ligera deseada de modo que cuando las dos cadenas pesadas y las dos cadenas ligeras del par de heterodímeros se coexpresan en una célula, la cadena pesada del primer heterodímero se empareja preferentemente con una de las cadenas ligeras en vez de con la otra. De manera similar, la cadena pesada del segundo heterodímero típicamente puede emparejarse preferentemente con la segunda cadena ligera en vez de con la primera.
MX2015006758A 2012-11-28 2013-11-28 Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. MX385344B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261730906P 2012-11-28 2012-11-28
US201361761641P 2013-02-06 2013-02-06
US201361818874P 2013-05-02 2013-05-02
US201361869200P 2013-08-23 2013-08-23
PCT/CA2013/050914 WO2014082179A1 (en) 2012-11-28 2013-11-28 Engineered immunoglobulin heavy chain-light chain pairs and uses thereof

Publications (2)

Publication Number Publication Date
MX2015006758A true MX2015006758A (es) 2016-06-10
MX385344B MX385344B (es) 2025-03-18

Family

ID=50826996

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015006758A MX385344B (es) 2012-11-28 2013-11-28 Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
MX2021000156A MX2021000156A (es) 2012-11-28 2015-05-28 Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.
MX2021009800A MX2021009800A (es) 2012-11-28 2015-05-28 Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2021000156A MX2021000156A (es) 2012-11-28 2015-05-28 Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.
MX2021009800A MX2021009800A (es) 2012-11-28 2015-05-28 Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.

Country Status (11)

Country Link
US (3) US10077298B2 (es)
EP (1) EP2925785A4 (es)
JP (4) JP6347490B2 (es)
KR (3) KR102545617B1 (es)
CN (3) CN120173124A (es)
AU (3) AU2013351888C1 (es)
CA (2) CA3206122A1 (es)
HK (1) HK1217496A1 (es)
MX (3) MX385344B (es)
RU (1) RU2720472C2 (es)
WO (1) WO2014082179A1 (es)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
PH12013500974A1 (en) 2010-11-17 2013-07-08 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
WO2012116927A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
MX341921B (es) 2011-02-28 2016-09-07 Hoffmann La Roche Proteinas de union a antigeno.
ES2676878T3 (es) 2011-03-03 2018-07-25 Zymeworks Inc. Diseño de armazón de heteromultímero multivalente y constructos
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
CA2878640C (en) 2012-07-13 2023-10-24 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
EP2904093B1 (en) 2012-10-03 2019-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
HK1231490A1 (zh) 2014-05-28 2017-12-22 Zymeworks, Inc. 修饰的抗原结合多肽构建体及其用途
EP3590961A1 (en) * 2015-03-25 2020-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bispecific multivalent fusion proteins
JP6952605B2 (ja) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド 多特異性抗原結合タンパク質
KR102669686B1 (ko) * 2015-04-28 2024-05-29 자임워크스 비씨 인코포레이티드 변형된 항원 결합 폴리펩티드 작제물 및 이의 용도
DK3313879T3 (da) 2015-06-24 2022-03-14 Hoffmann La Roche Anti-transferrinreceptor-antistoffer med tilpasset affinitet
CN108137706A (zh) 2015-07-15 2018-06-08 酵活有限公司 药物缀合的双特异性抗原结合构建体
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3356406A1 (en) 2015-10-02 2018-08-08 H. Hoffnabb-La Roche Ag Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
EP4524161A3 (en) * 2015-10-08 2025-06-04 Zymeworks BC Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
CR20180365A (es) 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CN106883297B (zh) * 2015-12-16 2019-12-13 苏州康宁杰瑞生物科技有限公司 基于ch3结构域的异二聚体分子、其制备方法及用途
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
EP3397646A1 (en) * 2015-12-28 2018-11-07 Massachusetts Institute of Technology Bispecific antibodies having constant region mutations and uses therefor
UA126900C2 (uk) 2016-04-28 2023-02-22 Чугаі Сейяку Кабусікі Кайся Антитіловмісний препарат
CN109475627B (zh) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
CN109790215B (zh) * 2016-09-29 2023-06-30 北京韩美药品有限公司 异源二聚体免疫球蛋白构建体和其制备方法
PE20191080A1 (es) * 2016-11-18 2019-08-20 Beijing Hanmi Pharmaceutical Co Ltd Anticuerpo biespecifico heterodimerico estructural de anticuerpo natural anti-pd-1/anti-her2 y metodo para preparar el mismo
CN110177564A (zh) * 2016-12-13 2019-08-27 德里尼亚公司 多价的调节t细胞调节剂
WO2018156785A1 (en) 2017-02-22 2018-08-30 Sutro Biopharma, Inc. Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
EP3609580A4 (en) * 2017-04-09 2021-03-24 Combio Pharmaceutical, Inc. COMMON LIGHT CHAIN BIPARATOPIC AND MULTIPARATOPIC ANTIBODIES AND METHOD OF USE
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
EP3625253A4 (en) 2017-05-16 2021-03-24 Scalmibio, Inc. ACTIVABLE ANTIBODIES AND THEIR METHODS OF USE
US20200079850A1 (en) 2017-05-24 2020-03-12 Sutro Biopharma, Inc. Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
KR102611853B1 (ko) * 2017-06-30 2023-12-08 자임워크스 비씨 인코포레이티드 안정화된 키메라 fabs
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
CN107602702A (zh) * 2017-09-22 2018-01-19 生标（上海）医疗器械科技有限公司 一种同时靶向人p185和血管内皮生长因子的抗体及其应用
IL273592B2 (en) 2017-09-29 2025-11-01 Chugai Pharmaceutical Co Ltd Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
JPWO2019088143A1 (ja) 2017-11-01 2020-11-12 中外製薬株式会社 生物活性が低下した抗体バリアントおよびアイソフォーム
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
US20240132626A1 (en) * 2018-04-13 2024-04-25 Eli Lilly And Company Fab-Based Trispecific Antibodies
US11492409B2 (en) 2018-06-01 2022-11-08 Novartis Ag Binding molecules against BCMA and uses thereof
JP2022515424A (ja) 2018-12-24 2022-02-18 サノフイ 突然変異ｆａｂドメインを有する多重特異性結合タンパク質
EP3966244A1 (en) * 2019-05-09 2022-03-16 F. Hoffmann-La Roche AG Methods of making antibodies
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
CN114173810B (zh) 2019-05-21 2024-09-06 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
KR20250156861A (ko) 2019-05-21 2025-11-03 노파르티스 아게 Cd19 결합 분자 및 이의 용도
CN110428870B (zh) * 2019-08-08 2023-03-21 苏州泓迅生物科技股份有限公司 一种预测抗体重链轻链配对概率的方法及其应用
WO2021026409A1 (en) 2019-08-08 2021-02-11 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
AU2020379735A1 (en) 2019-11-05 2022-05-26 Regeneron Pharmaceuticals, Inc. N-terminal SCFV multispecific binding molecules
US12091440B2 (en) 2019-12-20 2024-09-17 Regeneron Pharmaceuticals, Inc. IL2 and peptide-MHC complex fusion proteins and methods of use thereof
CN113121696A (zh) * 2019-12-31 2021-07-16 周易 Fab改造诱导形成的双特异性抗体及其制备方法和用途
EP4126241A1 (en) 2020-03-27 2023-02-08 Novartis AG Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
IL298007A (en) 2020-05-12 2023-01-01 Regeneron Pharma Novel il10 agonists and methods of use thereof
US11926667B2 (en) 2020-10-13 2024-03-12 Janssen Biotech, Inc. Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
WO2022097061A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
EP4271705A4 (en) * 2021-01-11 2025-06-25 Adimab, LLC Variant ch1 domains and variant cl domains engineered for preferential chain pairing and multi-specific antibodies comprising the same
BR112023022878A2 (pt) 2021-05-04 2024-01-23 Regeneron Pharma Agonistas do receptor fgf21 multiespecíficos e seus usos
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
BR112023023775A2 (pt) 2021-05-14 2024-02-20 Genentech Inc Métodos para tratar um indivíduo com um distúrbio proliferativo de células positivas para cd20 e para tratar uma população de indivíduos com um distúrbio proliferativo de células positivas para cd20
EP4373851A2 (en) 2021-07-19 2024-05-29 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
JP2024534787A (ja) 2021-08-16 2024-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規なｉｌ２７受容体アゴニスト及びその使用方法
CN118265726A (zh) * 2021-08-25 2024-06-28 广州凌腾生物医药有限公司 异源二聚体免疫球蛋白
EP4430079A1 (en) 2021-11-11 2024-09-18 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
CN114106192B (zh) * 2021-12-20 2024-06-14 广州爱思迈生物医药科技有限公司 双特异性抗体及其应用
US20250340668A1 (en) 2022-05-11 2025-11-06 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
CA3257348A1 (en) 2022-05-27 2023-11-30 Regeneron Pharmaceuticals, Inc. INTERLEUKIN-2 PROPROTEINS AND THEIR USES
AR129445A1 (es) 2022-05-27 2024-08-28 Glaxosmithkline Ip Dev Ltd USO DE PROTEÍNAS DE UNIÓN A TNF-a Y PROTEÍNAS DE UNIÓN A IL-7 EN EL TRATAMIENTO MÉDICO
CN119654338A (zh) 2022-06-04 2025-03-18 再生元制药公司 白细胞介素-2蛋白质原及其用途
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
KR20250048583A (ko) 2022-08-18 2025-04-09 리제너론 파아마슈티컬스, 인크. 인터페론 전구단백질 및 이의 용도
CN121177510A (zh) 2022-11-24 2025-12-23 广州百济神州生物制药有限公司 抗cea抗体药物缀合物和使用方法
EP4634220A2 (en) 2022-12-16 2025-10-22 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses
WO2024151978A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
AU2024207469A1 (en) 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
CN120603850A (zh) 2023-01-19 2025-09-05 广州百济神州生物制药有限公司 抗cmet抗体及使用方法
EP4658312A2 (en) * 2023-02-02 2025-12-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to follistatin polypeptides
WO2024182451A2 (en) 2023-02-28 2024-09-06 Regeneron Pharmaceuticals, Inc. Multivalent anti-spike protein binding molecules and uses thereof
KR20250156759A (ko) 2023-02-28 2025-11-03 리제너론 파아마슈티컬스, 인크. 다가 항스파이크 단백질 결합 분자 및 이의 용도
KR20250166361A (ko) 2023-02-28 2025-11-27 리제너론 파아마슈티컬스, 인크. Mhc 도메인 및 항원 펩티드를 포함하는 펩티드-mhc 착물 및 면역 세포 항원 표적화 모이어티를 포함하는 다중특이적 분자
AR132041A1 (es) 2023-03-03 2025-05-21 Beigene Switzerland Gmbh Anticuerpos cd16a y métodos de uso
TW202436343A (zh) 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1與cd16a抗體以及其使用方法
AR132043A1 (es) 2023-03-03 2025-05-21 Beigene Switzerland Gmbh Anticuerpos muc1 y métodos de uso
TW202436345A (zh) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 抗ｃｄ３多特異性抗體及使用方法
AR132064A1 (es) 2023-03-06 2025-05-21 Beigene Switzerland Gmbh Anticuerpos anti-cldn6 y métodos de uso
TW202436353A (zh) 2023-03-06 2024-09-16 瑞士商百濟神州瑞士有限責任公司 抗ｃｌｄｎ６與抗ｃｄ３多重特異性抗體以及使用方法
AU2024260531A1 (en) * 2023-04-28 2025-10-30 Xencor, Inc. Orthogonal multimeric proteins
WO2024233926A1 (en) 2023-05-10 2024-11-14 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
US20240376229A1 (en) 2023-05-12 2024-11-14 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof
CN121311500A (zh) * 2023-06-05 2026-01-09 美国普罗特欧洛吉克斯公司 抗体和产生抗体的方法
WO2024258785A1 (en) 2023-06-11 2024-12-19 Regeneron Pharmaceuticals, Inc. Circularized antibody molecules
WO2025106469A1 (en) 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof
WO2025122614A1 (en) 2023-12-05 2025-06-12 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
WO2025125137A1 (en) 2023-12-11 2025-06-19 Glaxosmithkline Intellectual Property Development Limited Baff specific antibodies
WO2025167974A1 (zh) * 2024-02-07 2025-08-14 上海齐鲁制药研究中心有限公司 多特异性抗体或抗原结合片段
WO2025184728A1 (en) * 2024-03-04 2025-09-12 Zymeworks Bc Inc. Multispecific and costimulatory antibody constructs and methods of use thereof
WO2025199243A1 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Trivalent multispecific binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025245494A1 (en) 2024-05-24 2025-11-27 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il12 receptor agonists
US20250376524A1 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Tetravalent multispecific binding molecules and methods of use thereof
WO2025255452A2 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses thereof
WO2025259718A2 (en) 2024-06-11 2025-12-18 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof
WO2025262216A1 (en) 2024-06-21 2025-12-26 Glaxosmithkline Intellectual Property Development Limited Multispecific antigen binding proteins binding to il23 and il18
WO2026021476A1 (en) 2024-07-24 2026-01-29 Beone Guangzhou Biologics Manufacturing Co., Ltd. Anti-cmet and anti-egfr multispecific antibody drug conjugates
WO2026025058A1 (en) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Aav viral particles retargeted to egfr-expressing cancer cells

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US731168A (en) 1902-06-16 1903-06-16 Clarence L Eaton Heel-seat and counter beating machine.
FI85768C (fi) 1990-07-04 1992-05-25 Valtion Teknillinen Foerfarande foer utfoerning av ytplasmonresonansmaetning samt i foerfarandet anvaendbar givare.
EP0517930B1 (en) 1991-06-08 1995-05-24 Hewlett-Packard GmbH Method and apparatus for detecting the presence and/or concentration of biomolecules
JPH08500017A (ja) 1992-08-17 1996-01-09 ジェネンテク，インコーポレイテッド 二特異的免疫アドヘジン
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
EP0904278A4 (en) 1996-03-22 1999-09-15 Human Genome Sciences Inc MOLECULE II INDUCER OF APOPTOSIS
GB9623820D0 (en) 1996-11-16 1997-01-08 Secr Defence Surface plasma resonance sensor
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
WO1999023105A1 (en) 1997-11-03 1999-05-14 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
ES2234241T3 (es) 1998-01-23 2005-06-16 Vlaams Interuniversitair Instituut Voor Biotechnologie Derivados de anticuerpo de multiples fines.
CA2319429A1 (en) 1998-05-20 1999-11-25 Graffinity Pharmaceutical Design Gmbh Surface plasmon resonance sensor for the simultaneous measurement of a plurality of samples in fluid form
US6289286B1 (en) 1998-05-29 2001-09-11 Biacore Ab Surface regeneration of biosensors and characterization of biomolecules associated therewith
AU2001245835A1 (en) 2000-03-15 2001-09-24 Heska Corporation Three-dimensional model of a complex between a Fc epsilon receptor alpha chain and a Fc region of an IgE antibody and uses thereof
US20030129659A1 (en) 2001-12-03 2003-07-10 Whelihan E. Fayelle Library screening
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
AU2004242614B2 (en) 2003-05-30 2011-09-22 Merus N.V. Fab library for the preparation of anti vegf and anti rabies virus fabs
US8005620B2 (en) * 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
WO2006031994A2 (en) 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
US8150634B1 (en) 2004-11-12 2012-04-03 Bristol-Myers Squibb Company Protein-ligand NOE matching for high-throughput structure determination
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
NZ591252A (en) 2006-03-17 2012-06-29 Biogen Idec Inc Methods of designing antibody or antigen binding fragments thereof with substituted non-covarying amino acids
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
WO2007137760A2 (en) 2006-05-25 2007-12-06 Bayer Schering Pharma Aktiengesellschaft Dimeric molecular complexes
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
MX2009010282A (es) 2007-03-29 2009-10-12 Genmab As Anticuerpos biespecificos y metodos para su produccion.
WO2009068649A2 (en) 2007-11-30 2009-06-04 Glaxo Group Limited Antigen-binding constructs
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
US20100075326A1 (en) 2008-09-12 2010-03-25 Cornell University Yeast surface two-hybrid system for quantitative detection of protein-protein interactions
CA2738568C (en) 2008-10-01 2024-02-20 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
KR20110104032A (ko) 2008-12-19 2011-09-21 마크로제닉스, 인크. 공유결합형 디아바디 및 이의 용도
CA2750533A1 (en) 2009-01-23 2010-07-29 Biogen Idec Ma Inc. Stabilized fc polypeptides with reduced effector function and methods of use
KR101431318B1 (ko) 2009-04-02 2014-08-20 로슈 글리카트 아게 전장 항체 및 단일쇄 ｆａｂ 단편을 포함하는 다중특이성 항체
JP5612663B2 (ja) 2009-04-07 2014-10-22 ロシュ グリクアート アクチェンゲゼルシャフト 二重特異性抗ＥｒｂＢ−１／抗ｃ−Ｍｅｔ抗体
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
CA2766220C (en) 2009-06-26 2021-02-09 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
CA2781539C (en) 2009-11-23 2021-07-20 Amgen Inc. Monomeric antibody fc
US10706955B2 (en) 2010-03-23 2020-07-07 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
WO2011120135A1 (en) 2010-03-29 2011-10-06 Zymeworks, Inc. Antibodies with enhanced or suppressed effector function
ES2989108T3 (es) 2010-04-20 2024-11-25 Genmab As Proteínas que contienen FC de anticuerpos heterodiméricos y métodos para producir las mismas
TW201742925A (zh) 2010-04-23 2017-12-16 建南德克公司 異多聚體蛋白質之製造
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
WO2012020096A1 (en) 2010-08-13 2012-02-16 Medimmune Limited Monomeric polypeptides comprising variant fc regions and methods of use
CA2808482C (en) 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
AU2011325833C1 (en) 2010-11-05 2017-07-13 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
MX349057B (es) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
CN102153650B (zh) 2011-01-27 2012-07-04 中国人民解放军军事医学科学院生物工程研究所 一种抗egfr人源化抗体l2-h3及其编码基因与应用
EP2688909A2 (en) * 2011-03-25 2014-01-29 Glenmark Pharmaceuticals S.A. Hetero-dimeric immunoglobulins
WO2012143523A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
EP2726504A1 (en) 2011-05-27 2014-05-07 Dutalys Antibodies with improved folding stability
RU2641256C2 (ru) 2011-06-30 2018-01-16 Чугаи Сейяку Кабусики Кайся Гетеродимеризованный полипептид
EP2543680A1 (en) 2011-07-07 2013-01-09 Centre National de la Recherche Scientifique Multispecific mutated antibody Fab fragments
RS56879B1 (sr) 2011-08-23 2018-04-30 Roche Glycart Ag Bispecifične molekule koje vezuju antigen za aktiviranje t ćelija
SG10201805291TA (en) 2011-10-27 2018-08-30 Genmab As Production of heterodimeric proteins
ES2732712T3 (es) 2011-10-31 2019-11-25 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
AU2012332021B8 (en) 2011-11-04 2017-10-12 Zymeworks Bc Inc. Stable heterodimeric antibody design with mutations in the Fc domain
DK2794905T3 (da) * 2011-12-20 2020-07-06 Medimmune Llc Modificerede polypeptider til bispecifikke antistofgrundstrukturer
WO2013152860A2 (en) 2012-04-11 2013-10-17 Dutalys Gmbh Improved antibody light chains
WO2013166594A1 (en) 2012-05-10 2013-11-14 Zymeworks Inc. Heteromultimer constructs of immunoglobulin heavy chains with mutations in the fc domain
US9499634B2 (en) 2012-06-25 2016-11-22 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
DE102012105864A1 (de) 2012-07-02 2014-02-20 Continental Reifen Deutschland Gmbh Fahrzeugluftreifen
EP2904093B1 (en) 2012-10-03 2019-04-10 Zymeworks Inc. Methods of quantitating heavy and light chain polypeptide pairs
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
MX385344B (es) 2012-11-28 2025-03-18 Zymeworks Bc Inc Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos.
US9914785B2 (en) * 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
HK1218930A1 (zh) 2013-02-08 2017-03-17 Abbvie Stemcentrx Llc 新型多特异性结构
ES2821753T3 (es) 2013-03-15 2021-04-27 Lilly Co Eli Procedimientos de producción de Fab y de anticuerpos biespecíficos
CA2910945A1 (en) 2013-05-08 2014-11-13 Zymeworks Inc. Bispecific her2 and her3 antigen binding constructs
KR20160044060A (ko) 2013-10-11 2016-04-22 에프. 호프만-라 로슈 아게 다중특이적 도메인 교환된 통상의 가변 경쇄 항체
EP3143043B1 (en) * 2014-05-16 2022-12-14 Pfizer Inc. Bispecific antibodies with engineered ch1-cl interfaces
HK1231490A1 (zh) * 2014-05-28 2017-12-22 Zymeworks, Inc. 修饰的抗原结合多肽构建体及其用途
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
JP6952605B2 (ja) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド 多特異性抗原結合タンパク質
EP4524161A3 (en) 2015-10-08 2025-06-04 Zymeworks BC Inc. Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
EP3397646A1 (en) 2015-12-28 2018-11-07 Massachusetts Institute of Technology Bispecific antibodies having constant region mutations and uses therefor
US11673971B2 (en) 2016-09-23 2023-06-13 Marengo Therapeutics, Inc. Multispecific antibody molecules comprising lambda and kappa light chains
CN110382537B (zh) 2017-02-02 2023-07-25 默克专利有限公司 抗体结构域的优选配对
US11685776B2 (en) 2017-03-02 2023-06-27 Novartis Ag Engineered heterodimeric proteins
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
BR112022005995A2 (pt) * 2019-09-30 2022-06-21 Adimab Llc Variantes do domínio ch1 projetadas para emparelhamento preferencial de cadeia leve e anticorpos multispecíficos compreendendo as mesmas
MX2022012541A (es) 2020-04-15 2022-11-07 Hoffmann La Roche Inmunoconjugados.

Also Published As

Publication number Publication date
KR20220086718A (ko) 2022-06-23
MX2021009800A (es) 2021-12-10
CA3206122A1 (en) 2014-06-05
KR20210070401A (ko) 2021-06-14
EP2925785A4 (en) 2016-11-16
KR20150103008A (ko) 2015-09-09
CA2893562A1 (en) 2014-06-05
CN120173125A (zh) 2025-06-20
AU2013351888C1 (en) 2018-10-11
MX385344B (es) 2025-03-18
US11286293B2 (en) 2022-03-29
KR102545617B1 (ko) 2023-06-20
AU2018220048A1 (en) 2018-09-06
JP2022116172A (ja) 2022-08-09
JP7080955B2 (ja) 2022-06-06
JP6347490B2 (ja) 2018-06-27
KR102411491B1 (ko) 2022-06-22
CN120173124A (zh) 2025-06-20
JP2016508117A (ja) 2016-03-17
AU2020239780A1 (en) 2020-10-22
HK1217496A1 (zh) 2017-01-13
HK1216899A1 (zh) 2016-12-09
US10077298B2 (en) 2018-09-18
AU2020239780B2 (en) 2023-06-29
CA2893562C (en) 2023-09-12
RU2720472C2 (ru) 2020-04-30
EP2925785A1 (en) 2015-10-07
US20150307594A1 (en) 2015-10-29
KR102264570B1 (ko) 2021-06-14
JP6797862B2 (ja) 2020-12-09
CN105026430B (zh) 2025-03-25
AU2018220048B2 (en) 2020-06-25
AU2013351888B2 (en) 2018-05-24
BR112015012385A2 (pt) 2019-08-27
JP2018162253A (ja) 2018-10-18
MX2021000156A (es) 2021-03-25
RU2015125486A (ru) 2017-01-10
JP2021048850A (ja) 2021-04-01
AU2013351888A1 (en) 2015-06-04
US20190085055A1 (en) 2019-03-21
US20220227840A1 (en) 2022-07-21
CN105026430A (zh) 2015-11-04
WO2014082179A1 (en) 2014-06-05
US12304945B2 (en) 2025-05-20

Similar Documents

Publication Publication Date Title
MX2015006758A (es) Pares de cadena pesada-cadena ligera de inmunoglobulina modificados geneticamente y usos de estos.
MX2016015459A (es) Construcciones polipeptidicas de union al antigeno modificadas y usos de estas.
EP3671895A4 (en) BATTERY MODULE, BATTERY PACK INCLUDING BATTERY MODULE AND VEHICLE INCLUDING BATTERY PACK
EP3654444A4 (en) BATTERY MODULE INTEGRATED IN A COOLING AND FIXING STRUCTURE OF BATTERY ELEMENTS, AND BATTERY PACK INCLUDING IT
EP3627592A4 (en) BATTERY MODULE WITH ENHANCED SECURITY, BATTERY PACK INCLUDING BATTERY MODULE AND VEHICLE INCLUDING BATTERY PACK
MX2016002761A (es) Polarizador reflectante de multiples capas.
EP3584876A4 (en) BATTERY MODULE AND BATTERY PACK
EA201990032A1 (ru) Способы и композиции для терапии посредством потенциирования стволовых клеток
DK3243840T3 (da) Bispecifikt antistof eller antistofblanding med fælles lette kæder
SV2017005598A (es) Derivados de amidas policiclicas como inhibidores de cdk9
EP3567669A4 (en) BATTERY MODULE, BATTERY PACK COMPRISING THE BATTERY MODULE, AND AUTOMOBILE COMPRISING THE BATTERY PACK
CL2017002156A1 (es) Uso de inhibidores de la telomerasa para el tratamiento de trastornos mieloproliferativos y neoplasias mieloproliferativas.
EP3382788A4 (en) BATTERY UNIT, BATTERY MODULE AND BATTERY PACK
MX2014005301A (es) Estructuras de iluminacion y de luminarias.
CL2017001506A1 (es) Sistema de enlace de oruga reversible
EP4047737A4 (en) Battery cell, battery module comprising same battery cell, and battery pack comprising same battery module
EP3644401A4 (en) BATTERY MODULE, AND BATTERY BLOCK AND CONTAINING VEHICLE
EP3972005A4 (en) Battery module, battery pack, and vehicle
HUE069402T2 (hu) Fokozott hûtési hatékonyságú akkumulátormodul és azt tartalmazó akkumulátorcsomag
EP3930026C0 (en) BATTERY MODULE, BATTERY PACK AND VEHICLE
MX2016007060A (es) Polarizador reflectante multicapa con elementos absorbentes embebidos.
FI20165422A7 (fi) Akkumoduuli, komponentit ja menetelmä
BR112016017436A2 (pt) Item de bagagem de volume variado
PE20141721A1 (es) Dispositivo de retencion
EP3675208A4 (en) BATTERY MODULE AND BATTERY PACK INCLUDING IT